Harbin Honz Pharmaceutical Co., Ltd. Board of Directors Compensation and Assessment Committee Audit Opinion on the Fulfillment of Conditions for the Second Tranche of Restricted Stock Unlock for the First Grant of the 2024 Restricted Stock Incentive Plan
Harbin Honz Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") Compensation and Assessment Committee, in accordance with the "Shenzhen Stock Exchange Stock Listing Rules," "Administrative Measures for Equity Incentives of Listed Companies," and other laws, regulations, and the "Company Articles of Association," has reviewed the list of incentive recipients for the second tranche unlock of the first grant of the Company's 2024 Restricted Stock Incentive Plan and hereby expresses its audit opinion as follows:
Upon review, the incentive recipients for the unlock of the first grant of the Company's 2024 Restricted Stock Incentive Plan meet the requirements of the "Administrative Measures for Equity Incentives of Listed Companies," the "2024 Restricted Stock Incentive Plan (Draft)," and the "2024 Restricted Stock Incentive Plan Implementation and Assessment Management Measures," among other relevant laws, regulations, and normative documents. The unlock qualification of the incentive recipients is legal and valid, and the conditions for the second unlock period of the first grant have been fully met. Therefore, it is agreed to proceed with the unlock of restricted shares for 92 eligible incentive recipients. The number of restricted shares to be unlocked in this batch is 14,267,400 shares, and it is agreed to submit this matter to the Board of Directors for deliberation.